Dr. Timour Balsan, PHD

Leveraging comparative oncogenomics to nominate therapeutic targets for hypodiploid B-ALL.

Hypodiploid B-cell Acute Lymphoblastic Leukemia (B-ALL) is a disease from which few survive. Developing treatments for this disease has been challenging because we did not have the tools to study it. We have developed novel experimental tools, namely animal models, that are allowing us to develop therapies for the disease.